Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon ...
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...
Medscape1 天
ctDNA Testing Shows Promise in Guiding CRC Treatment Decisions
New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in early-stage colorectal cancer.
Knowridge2 天
Blood test can guide drug use in treating stage 3 colon cancer
A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...
GlobalData on MSN3 天
Natera reports new data from Phase III study of colorectal cancer detection test
Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...
来自MSN2 天
ctDNA Testing Shows Promise for Influencing Colorectal Cancer Treatment
Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...
Understanding the Link Between Gastric Ulcers and Stomach Cancer Risk
As gastroenterology research progresses, it is critical to comprehend the connection between stomach cancer and gastric ...
EurekAlert!5 天
Blood test from Alliance trial guides use of anti-inflammatory drug to lower colon cancer ...
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...
Armed robbery in Revesby5 天
Blood Test Guides Drug to Cut Colon Cancer Recurrence
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...